The drug Enbrel (also know by its generic name etanercept) is a TNF-alpha inhibitor that was approved for people with psoriatic arthritis in January 2002 and for moderate-to-severe psoriasis in April 2004. In November 2016, the psoriasis indication was extended to include pediatric patients ages 4 years and older. It also is approved for treating rheumatoid arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
Enbrel is given by injection under the skin at once a week for patients with psoriatic arthritis. For adults with moderate-to-severe psoriasis, Enbrel is administered twice-weekly by injections under the skin for 3 months, and then a maintenance dose once per week. Enbrel is administered weekly in pediatric patients with moderate-to-severe psoriasis.
To learn more, please visit the Enbrel website.